Clinical trials: Prostate Carcinoma
Prostate Cancer
CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone
This is a phase II clinical trial in patients with metastatic castration sensitive prostate cancer. The objective of the study is to determine the efficacy and further define the safety of the treatment combination.
- Trial name
- NCT03934840
- Testing
- Cabazitaxel, Carboplatin, Abiraterone
- Where
- 8 sites in United States
- Volunteers
- 61 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Breast Carcinoma, Colon Carcinoma
Clinical Outcomes for Offering Genetic Testing in a Tiered Approach
This clinical quality improvement study reviews and develops a clinical operations workflow to identify cancer patients who meet criteria for genetic counseling and testing.
- Conditions
- Breast Carcinoma, Colon Carcinoma, Malignant Solid Neoplasm, Ovarian Carcinoma
- Trial name
- NCT04902144
- Testing
- Electronic Health Record Review, Questionnaire Administration, Behavioral Intervention
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Fred Hutchinson Cancer Center
Prostate Cancer
IGF Inhibition With Xentuzumab Prior to Radical Prostatectomy
The WINGMEN trial aims to understand how a hormone-like protein called insulin-like growth factor (IGF) helps prostate cancers grow and become aggressive.
- Trial name
- WINGMEN (NCT05110495)
- Testing
- Xentuzumab
- Where
- United Kingdom
- Volunteers
- 27 people
- Sponsor
- University of Oxford
Prostate Cancer
Fusion Targeted Biopsy of the Prostate
The objective of the proposed study is to evaluate a new, molecular image directed, three-dimensional (3D) ultrasound guided biopsy system in human patients. The current biopsy uses ultrasound imaging as guidance.
- Trial name
- NCT02013414
- Testing
- 3D ultrasound-guided biopsy
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Emory University
Prostate Cancer
Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer
Background: Enzalutamide is given to treat metastatic prostate cancer. But it takes 4 pills to deliver the effective dose. This can be difficult for people already taking multiple drugs.
- Trial name
- NCT03478904
- Testing
- Enzalutamide Liquid, Enzalutamide Capsule
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Bone Metastases
ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain
A study to evaluate the safety and initial effectiveness of the ExAblate 2100 Conformal Bone System in the treatment of pain resulting from metastatic bone tumors.
- Trial name
- NCT00981578
- Testing
- ExAblate 2100
- Where
- 5 sites in United States
- Volunteers
- 37 people
- Sponsor
- InSightec
Prostate Cancer
GM-CSF for Maintenance of Prostate Cancer for Patients Responding to Taxotere
This trial is designed to investigate the efficacy and safety of GM-CSF used as a maintenance program in patients with androgen-independent prostate cancer (AIPC) who have achieved a maximal response on a taxotere or other…
- Trial name
- NCT00274287
- Testing
- GM CSF
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Oncology Specialists, S.C.
Metastatic Castration Resistant Prostate Cancer
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
The purpose of this study is to determine how participants with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib versus treatment…
- Trial name
- TRITON3 (NCT02975934)
- Testing
- Rucaparib, Abiraterone acetate or Enzalutamide or Docetaxel
- Where
- 150 sites in United States, Australia and 10 more
- Volunteers
- 405 people
- Sponsor
- pharmaand GmbH
Prostate Cancer
Safety Study of MRI-guided Transurethral Ultrasound Ablation of Prostate Tissue to Treat Localized Prostate Cancer
This study is to evaluate that the magnetic resonance imaging (MRI)-guided transurethral ultrasound therapy system is safe and feasible to ablate prostate tissue in men with localized prostate cancer.
- Trial name
- NCT01686958
- Testing
- MR-Guided Transurethral US Ablation of Prostate Tissue
- Where
- 3 sites in United States, Canada and 1 more
- Volunteers
- 30 people
- Sponsor
- Profound Medical Inc.
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer
This phase II trial studies how well pembrolizumab and HER2Bi-armed activated T cells work in treating patients with castration resistant prostate cancer that has spread to other places in the body.
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, PSA Progression
- Trial name
- NCT03406858
- Testing
- HER2Bi-Armed Activated T Cells, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Hormone-Resistant Prostate Cancer, Metastatic Prostatic Adenocarcinoma
Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel
This phase II trial studies how well giving phenelzine sulfate together with docetaxel works in treating patients with prostate cancer that is growing, spreading, or getting worse after first-line therapy with docetaxel.
- Conditions
- Hormone-Resistant Prostate Cancer, Metastatic Prostatic Adenocarcinoma, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
- Trial name
- NCT01253642
- Testing
- Biopsy of Prostate, Docetaxel, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- OHSU Knight Cancer Institute
Prostate Cancer
A Couple Support Intervention for Prostate Cancer
Even with careful prostate surgery, men find it difficult to have an erection. Our previous research shows that couples are not often supported to cope with the effects of surgery on their sexual relationships.
- Trial name
- NCT01842438
- Testing
- Behavioral: psychosexual intervention
- Where
- United Kingdom
- Volunteers
- 86 people
- Sponsor
- University of Stirling
Prostate Cancer
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
The purpose of the study is to determine whether lenalidomide is safe and effective for use in combination with docetaxel and prednisone for the treatment of subjects with metastatic Castrate-Resistant Prostate Cancer.
- Trial name
- Mainsail (NCT00988208)
- Testing
- Lenalidomide, Docetaxel, Prednisone
- Where
- 210 sites in United States, Australia and 19 more
- Volunteers
- 1,059 people
- Sponsor
- Celgene
Prostate Cancer, Prostate Adenocarcinoma
Pilot Trial Evaluating Stereotactic Body Radiotherapy With Integrated Boost for Clinically Localized Prostate Cancer (RAD 1203)
This study will investigate the safety, tolerability, and effectiveness of giving a higher dose to the part of the prostate which contains the cancer while giving a standard radiation dose to the entire prostate.
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Radiation Toxicity, Sexual Dysfunction
- Trial name
- NCT01856855
- Testing
- Stereotactic Body Radiation Therapy with Integrated Boost
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- John Fiveash, MD
Prostate Cancer
BioProtect Balloon Implant™ Balloon System Pivotal Study BP-007
The BioProtect Balloon Implant™ System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of the balloon to…
- Trial name
- NCT03400150
- Testing
- balloon, Control
- Where
- 16 sites in United States, Israel and 4 more
- Volunteers
- 222 people
- Sponsor
- BioProtect
Prostate Cancer
Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer
Background: Enzalutamide is a well tolerated hormone therapy that is used to treat advanced prostate cancer. It is given to help kill cancer cells and limit cancer cell growth.
- Trial name
- NCT01875250
- Testing
- PROSTVAC-F (Fowlpox)/TRICOM, PROSTVAC-V (Vaccinia)/TRICOM, Enzalutamide (Xtandi)
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- National Cancer Institute (NCI)
Prostatic Neoplasms
A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer
The purpose of this study was to determine the efficacy and safety of oral enzalutamide compared to bicalutamide in castrate men with metastatic prostate cancer who have progressed while on Luteinizing Hormone Receptor Hormone…
- Trial name
- NCT01288911
- Testing
- enzalutamide, bicalutamide
- Where
- 88 sites in United States, Belgium and 6 more
- Volunteers
- 375 people
- Sponsor
- Astellas Pharma Inc
Prostate Cancer
Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen Blockade
A growing body of literature supports the role of angiogenesis in the development and spread of a variety of human cancers including prostate cancer.
- Trial name
- NCT00945477
- Testing
- Pazopanib (GW786034)
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- Illinois CancerCare, P.C.
Adenocarcinoma of the Prostate, Castration-resistant Prostate Cancer
Cabozantinib in Men With Castration-Resistant Prostate Cancer
This pilot clinical trial studies cabozantinib in treating men with castration-resistant prostate cancer. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Adenocarcinoma of the Prostate, Castration-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage III Prostate Cancer
- Trial name
- NCT01703065
- Testing
- Cabozantinib
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Washington
Prostate Cancer
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells and shrink tumors. Androgens can cause the growth of prostate cancer cells.
- Trial name
- NCT00936390
- Testing
- bicalutamide, flutamide, LHRH agonist (antagonist) therapy
- Where
- 518 sites in United States, Canada
- Volunteers
- 1,538 people
- Sponsor
- Radiation Therapy Oncology Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.